2. Academic Validation
  3. Inhibition of Ephrin B2 Reverse Signaling Suppresses Multiple Myeloma Pathogenesis

Inhibition of Ephrin B2 Reverse Signaling Suppresses Multiple Myeloma Pathogenesis

  • Cancer Res. 2024 Jan 17. doi: 10.1158/0008-5472.CAN-23-1950.
Joshua P Sasine 1,  Natalia Y Kozlova 1,  Lisa Valicente 1,  Jennifer Dukov 1,  Dana H Tran 2,  Heather A Himburg 3,  Sanjeev Kumar 1,  Sarah Khorsandi 1,  Aldi Chan 4,  Samantha Grohe 1,  Michelle Li 5,  Jenny Kan 5,  Mary E Sehl 6,  Gary J Schiller 5,  Bryanna Reinhardt 7,  Brijesh Kumar Singh 8,  Ritchie Ho 1,  Peibin Yue 1,  Elena B Pasquale 9,  John P Chute 1
Affiliations

Affiliations

  • 1 Cedars-Sinai Medical Center, Los Angeles, CA, United States.
  • 2 cedars sinai, Los Angeles, CA, United States.
  • 3 Medical College of Wisconsin, Milwaukee, WI, United States.
  • 4 Cedars Sinai, United States.
  • 5 David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.
  • 6 University of California, Los Angeles, Los Angeles, CA, United States.
  • 7 Louisiana State University Health Sciences Center New Orleans, New Orleans, LA, United States.
  • 8 Cedars-Sinai Medical Center, United States.
  • 9 Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States.
PMID: 38231476 DOI: 10.1158/0008-5472.CAN-23-1950
Abstract

Bone marrow vascular endothelial cells (BM ECs) regulate multiple myeloma (MM) pathogenesis. Identification of the mechanisms underlying this interaction could lead to the development of improved strategies for treating MM. Here, we performed a transcriptomic analysis of human ECs with high capacity to promote MM growth, revealing overexpression of the Receptor Tyrosine Kinases, EphB1 and EphB4, in MM - supportive ECs. Expression of Ephrin B2 (EFNB2), the binding partner for EphB1 and EphB4, was significantly increased in MM cells. Silencing EphB1 or EphB4 in ECs suppressed MM growth in co-culture. Similarly, loss of EFNB2 in MM cells blocked MM proliferation and survival in vitro, abrogated MM engraftment in immune-deficient mice, and increased MM sensitivity to chemotherapy. Administration of an EFNB2-targeted single chain variable fragment also suppressed MM growth in vivo. In contrast, overexpression of EFNB2 in MM cells increased STAT5 activation, increased MM cell survival and proliferation, and decreased MM sensitivity to chemotherapy. Conversely, expression of mutant EFNB2 lacking reverse signaling capacity in MM cells increased MM cell death and sensitivity to chemotherapy and abolished MM growth in vivo. Complementary analysis of MM patient data revealed that increased EFNB2 expression is associated with adverse-risk disease and decreased survival. This study suggests that EFNB2 reverse signaling controls MM pathogenesis and can be therapeutically targeted to improve MM outcomes.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-101853
    98.39%, STAT5抑制剂
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z